{
  "abstract": "Abstract Overview of: European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024[Accessed 22 May 2025].",
  "authors": [
    {
      "affiliations": [],
      "name": "BMJ Publishing Group Ltd"
    }
  ],
  "title": "Risk of secondary T-cell malignancy after CAR T-cell therapy",
  "uid": "cf400019-4a68-5074-b299-60a7955e103d"
}